Guoxin Securities released a research report on April 23 stating that it gave Ed Biotech (300685.SZ) a purchase rating. The main reasons for the rating include: 1) revenue surpassed 1 billion dollars for the first time, and the leading position in the hospital market is stable; 2) the accelerated transformation of testing to in-hospital, domestic and international two-wheel drive; 3) gross margin is rising steadily, and the scale effect continues to be prominent in the new industry environment. (Mainichi Keizai Shimbun)
国信证券4月23日发布研报称，给予艾德生物（300685.SZ）买入评级。评级理由主要包括：1）营收首次突破10亿，院内市场龙头地位稳固；2）检测加速向院内转变，国内国际双轮驱动；3）毛净利率稳中有升，新行业环境下规模效应不断凸显。（每日经济新闻）
Guoxin Securities released a research report on April 23 stating that it gave Ed Biotech (300685.SZ) a purchase rating. The main reasons for the rating include: 1) revenue surpassed 1 billion dollars for the first time, and the leading position in the hos
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.